Boston IVF-The Eugin Group, Waltham, Massachusetts; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, Massachusetts.
Department of Obstetrics and Gynecology, Lenox Hill Hospital-Zucker School of Medicine at Hofstra/Northwell, New York, New York.
Fertil Steril. 2022 Sep;118(3):550-559. doi: 10.1016/j.fertnstert.2022.05.025. Epub 2022 Jun 11.
To determine the association of interpregnancy interval on perinatal outcomes and whether this was influenced by mode of conception.
Retrospective cohort.
Centers for Disease Control and Prevention's natality national database.
PATIENT(S): Patients who had an index singleton live birth with a preceding live birth. Index pregnancies from 2016 to 2019 were conceived with in vitro fertilization (IVF) (n = 32,829) or ovulation induction/intrauterine insemination (OI/IUI) (n = 23,016) or without assistance (n = 7,564,042).
INTERVENTION(S): None.
MAIN OUTCOME MEASURE(S): The primary outcomes evaluated were preterm birth (<37 weeks) and low birth weight (<2,500 g). Multivariable logistic regression was performed to evaluate the association of interpregnancy intervals with perinatal outcomes stratified by mode of conception. Adjusted odds ratios and 95% confidence intervals (CIs) were presented.
RESULT(S): Compared with the interpregnancy interval reference group of 12 to <18 months, a <12 month interpregnancy interval was associated with an increase in preterm birth (<37 weeks) for pregnancies conceived with OI/IUI or without assistance (aOR, 1.42; 95% CI, 1.16-1.74, and aOR, 1.14; 95% CI, 1.13-1.15, respectively), whereas IVF was not associated with an increase (aOR, 0.90; 95% CI, 0.77-1.04). A <12 month interpregnancy interval was associated with an increase in low birth weight for pregnancies conceived with IVF or OI/IUI or without assistance (aOR, 1.34; 95% CI, 1.09-1.64; aOR, 1.33; 95% CI, 1.01-1.76; and aOR, 1.26; 95% CI, 1.24-1.27, respectively).
CONCLUSION(S): An interpregnancy interval of at least 12 months reduces adverse perinatal outcomes for pregnancies conceived with and without infertility treatment.
确定孕间隔与围产期结局的关系,并确定这种关系是否受受孕方式的影响。
回顾性队列研究。
疾病控制与预防中心的出生率国家数据库。
有一次指数单活产且前次活产的患者。2016 年至 2019 年期间,指数妊娠通过体外受精(IVF)(n=32829)或排卵诱导/宫腔内人工授精(OI/IUI)(n=23016)或未经辅助受孕(n=7564042)。
无。
主要结局评估早产(<37 周)和低出生体重(<2500g)。对受孕方式分层的孕间隔与围产期结局进行多变量逻辑回归分析。呈现调整后的优势比和 95%置信区间(CI)。
与 12 至<18 个月的孕间隔参考组相比,OI/IUI 或未经辅助受孕的<12 个月孕间隔与早产(<37 周)的风险增加相关(调整后的优势比,1.42;95%CI,1.16-1.74,和调整后的优势比,1.14;95%CI,1.13-1.15),而 IVF 与风险增加无关(调整后的优势比,0.90;95%CI,0.77-1.04)。对于 IVF、OI/IUI 或未经辅助受孕的妊娠,<12 个月的孕间隔与低出生体重的风险增加相关(调整后的优势比,1.34;95%CI,1.09-1.64;调整后的优势比,1.33;95%CI,1.01-1.76;和调整后的优势比,1.26;95%CI,1.24-1.27)。
至少 12 个月的孕间隔可降低不孕治疗和未经治疗受孕的妊娠的不良围产期结局。